HLA-DQ (MHC II) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone SPM422 ]
- 产品详情
- 实验流程
- 背景知识
Application
| IHC, IF, FC |
|---|---|
| Primary Accession | P01908 |
| Other Accession | 3117, 3118, 3119, 550475, P01909, P01920 |
| Reactivity | Human, Pig |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgG2a, kappa |
| Clone Names | SPM422 |
| Calculated MW | 60 KDa |
| Application Note | IHC~~1:100~500 IF~~1:50~200 FC~~1:10~50 |
|---|---|
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
| Precautions | HLA-DQ (MHC II) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
For Research Use Only. Not For Use In Diagnostic Procedures.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
Recognizes a DQ antigen, which is a dimer of 60kDa. The class II molecule is a heterodimer consisting of an alpha (DQA) and a beta chain (DQB), both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B Lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35kDa. It is encoded by 5 exons; exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. Within the DQ molecule both the alpha chain and the beta chain contain the polymorphisms specifying the peptide binding specificities, resulting in up to four different molecules. Typing for these polymorphisms is routinely done for bone marrow transplantation.ĀThis MAb strongly blocks cytotoxicity activity of T4-positive cytotoxic T cell clones.
REFERENCES
Spits H; Keizer G; Borst J; Terhorst C; Hekman A; de Vries JE. Characterization of monoclonal antibodies against cell surface molecules associated with cytotoxic activity of natural and activated killer cells and cloned CTL lines. Hybridoma, 1983, 2(4):423-37. | Spits H., Borst J., Giphan M., Coligan J., Terhorst C. and de Vries J., Eur. J. Immunol. 14, (1984). | Bontrop R., Schreuder G., Mikalski E., van Miltenburg R. and Giphan M., Tissue Antigens, 27, (1986). |
终于等到您。ABCEPTA(百远生物)抗体产品。
点击下方“我要评价 ”按钮提交您的反馈信息,您的反馈和评价是我们最宝贵的财富之一,
我们将在1-3个工作日内处理您的反馈信息。
如有疑问,联系:0512-88856768 tech-china@abcepta.com.
















癌症的基本特征包括细胞增殖、血管生成、迁移、凋亡逃避机制和细胞永生等。找到癌症发生过程中这些通路的关键标记物和对应的抗体用于检测至关重要。
为您推荐一个泛素化位点预测神器——泛素化分析工具,可以为您的蛋白的泛素化位点作出预测和评分。
细胞自噬受体图形绘图工具为你的蛋白的细胞受体结合位点作出预测和评分,识别结合到自噬通路中的蛋白是非常重要的,便于让我们理解自噬在正常生理、病理过程中的作用,如发育、细胞分化、神经退化性疾病、压力条件下、感染和癌症。